Skip to main content
. 2022 Nov 22;40(2):585–600. doi: 10.1007/s12325-022-02369-x

Table 2.

Baseline patient characteristics

Rimegepant/rimegepant OLE (n = 348) Placebo/rimegepant OLE (n = 347) Total (n = 695)
Age, years 41.4 (13.0) 41.2 (13.3) 41.3 (13.1)
Sex
 Women 282 (81%) 295 (85%) 577 (83%)
 Men 66 (19%) 52 (15%) 118 (17%)
History of chronic migraine
 Yes 74 (21%) 89 (26%) 163 (23%)
 No 274 (79%) 258 (74%) 532 (77%)
Primary migraine type
 Without aura 185 (53%) 193 (56%) 378 (54%)
 With aura 163 (47%) 154 (44%) 317 (46%)

Data are mean (SD) or n (%)

OLE open-label extension